Your Health, We Care
In June 2024, Roche announced that the European Commission and the US FDA had approved Alectinib (trade name Alecensa) as an adjuvant therapy for adult ALK positive NSCLC patients at high risk of recurrence after tumor resection.
With the deepening of research on Alectinib, its therapeutic potential in other types of tumors and its combination therapy with other drugs may be explored in the future.
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
